The cause of endocardial elastosis, also known as endocardial sclerosis, is not yet known. It is one of the more common types of pediatric primary cardiomyopathy, also known as primary endocardial elastosis. The main therapy is to control heart failure. Acute heart failure requires intravenous digoxin or cetiran fast digitalis and should be maintained with long doses of digoxin for up to 2-3 years or more, until the heart retracts to normal, premature discontinuation of the drug can lead to worsening of the disease. In recent years, add and Kaipotong long-term oral, to improve cardiac function has a certain effect on critical cases add dobutamine, dobutamine, tachyphylaxis and corticosteroid treatment (see section on congestive heart failure and cardiogenic shock). Antibiotics are appropriate to control pulmonary infections. In cases of combined mitral valve insufficiency, valve replacement should be performed, and cardiac function may improve after surgery. Heart transplantation is considered for those with severely enlarged hearts, severely reduced ejection fraction and poor response to drug therapy. Considering that the pathogenesis of this disease may be related to immune dysfunction, immunosuppressive therapy has been applied in recent years, mainly with prednisone 1.5mg/(kg?), and the dosage is gradually reduced after 8 weeks, by 2.5~1.25mg every 2 weeks to 0.25~5mg daily as maintenance dosage, until the electrocardiogram is normal and the heart is close to normal on X-ray chest radiograph, and then the drug is gradually discontinued for 1~1.5 years.